Key insights
- Barclays upgraded Sonova to "overweight" from "underweight", citing its Phonak EON hearing aids' potential to drive market share gains at the expense of competitors like Demant. A survey of US audiologists indicated strong product differentiation for EON and improving demand, with reduced macroeconomic impact on patient behavior. Barclays also lowered GN Store Nord to "equal weight".

Investing.com -- Barclays has upgraded Sonova to "overweight" from "underweight", identifying the Swiss hearing-aid manufacturer as its preferred investment in the sector as its latest survey of U.S. audiologists points to improving demand for its newest products.
The brokerage raised its price target to CHF330 from CHF220, arguing that Sonova's Phonak EON hearing aids could help the company gain market share at the expense of competitors, particularly Demant. Barclays expects Sonova's earnings growth to accelerate, with further potential upside as its product portfolio expands.
The bank's survey of 148 independent US audiologists found that Phonak is expected to gain about 197 basis points of market share over the next six months. Demant's Oticon brand is projected to lose 140 basis points, while GN Store Nord's ReSound is expected to shed 21 basis points.
Phonak EON received the strongest product differentiation assessment, with 78% of respondents describing it as moderately or significantly better than existing offerings. Demant's Oticon Reveal received a 76% positive assessment, while GN's ReSound Sensia scored 59%.
Barclays also highlighted improved fulfilment rates for EON compared with its predecessor, rising to 94% from 64%, and said the product's smaller form factor addresses a previous weakness.
The survey pointed to easing pressure on consumer demand. Some 34% of audiologists reported negligible or no impact from macroeconomic uncertainty on patient behaviour, compared with 18% in the June survey. The proportion reporting an increase in patient cancellations and no-shows fell to 16% from 33%.
Expectations for patient deferrals also improved, with 25% anticipating an increase over the next six months, compared with 51% in June. However, Barclays cautioned that the recovery is increasingly reflected in sector valuations.
Barclays lowered GN Store Nord to "equal weight" from "overweight", although it raised its price target to DKK129 from DKK123. The brokerage said the shares had gained 32% over three months, outperforming the sector's 12% advance, leaving less scope for further gains.
It maintained "equal weight" ratings on Demant and Amplifon, citing expected market-share losses at the former and integration and leverage risks at the latter. Barclays also sees potential for Sonova to introduce an instant-fit competitor to Demant's Oticon Zeal in 2027, providing another possible source of growth.
Original Article